Figure 4.

BBR stimulates the activation of tumor-infiltrating T-cells. (A), (B) and (C) C57BL/6 mice (n = 5) with subcutaneous Lewis tumor were i.p. treated with PBS or BBR (4 and 8 mg/kg). The populations of CD8⁺ (A), CD8⁺/CD4⁺ (B) in CD3⁺ TILs, and CD69⁺CD137⁺ in CD3⁺CD8⁺ TILs (C) were analyzed by flow cytometry. (D) and (E) Representative flow cytometric plots and quantification of IFN-γ expression (D) and GzmB level (E) in CD3⁺CD8⁺ TILs from PBS or BBR-treated Lewis tumor was measured by flow cytometry. (F) and (G) Representative flow cytometric plots and quantification of MDSCs (F) number and Tregs (G) number in PBS or BBR-treated Lewis tumor. Data shown are mean value ± standard error of mean (SEM). ^∗P < 0.05, ^∗∗P < 0.01 and ^∗∗∗P < 0.001 compared with PBS group.